Literature DB >> 3315699

Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin.

D R Newell1, Z H Siddik, L A Gumbrell, F E Boxall, M E Gore, I E Smith, A H Calvert.   

Abstract

Plasma free platinum (less than 50,000 mol. wt) pharmacokinetics have been studied in eight patients treated with high-dose (800-1600 mg/m2) carboplatin as a 1 h infusion with moderate hydration. Following the infusion, levels decayed biphasically with half-lives (means +/- S.D.) of 83 +/- 15 min and 6.1 +/- 2.8 h. The plasma free platinum area under the concentration vs. time curve (AUC) at 1600 mg/m2 in five patients was 23 +/- 2 mg carboplatin/ml.min. Comparison with data at conventional doses (less than or equal to 500 mg/m2) gave no indication of non-linear kinetics. Total body clearance of free platinum was found to correlate with glomerular filtration rate (r = 0.769, P = 0.03), and haematological toxicity, white cell nadir and duration of thrombocytopenia, correlated with plasma free platinum AUC (r = 0.784, P = 0.02 and r = 0.885, P = 0.01, respectively). Persistence of platinum was demonstrated in tissues removed at autopsy from a patient who had received carboplatin 14 days earlier. Highest platinum levels were found in the liver, kidney, skin and small cell lung tumour.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3315699     DOI: 10.1016/0277-5379(87)90126-x

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  22 in total

Review 1.  Pharmacokinetically guided administration of chemotherapeutic agents.

Authors:  H J van den Bongard; R A Mathôt; J H Beijnen; J H Schellens
Journal:  Clin Pharmacokinet       Date:  2000-11       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics and dose optimisation of carboplatin.

Authors:  S B Duffull; B A Robinson
Journal:  Clin Pharmacokinet       Date:  1997-09       Impact factor: 6.447

Review 3.  Adaptive control methods for the dose individualisation of anticancer agents.

Authors:  A Rousseau; P Marquet; J Debord; C Sabot; G Lachâtre
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

4.  Cerebrospinal fluid pharmacokinetics of carboplatin in children with brain tumors.

Authors:  R Riccardi; A Riccardi; C Di Rocco; G Carelli; R L Tartaglia; A Lasorella; T Servidei; R Mastrangelo
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma.

Authors:  D R Newell; R A Eeles; L A Gumbrell; F E Boxall; A Horwich; A H Calvert
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

6.  Pharmacokinetics of cisplatin given at a daily low dose as a radiosensitiser.

Authors:  G Milano; V Troger; A Courdi; X Fontana; P Chauvel; J L Lagrange
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 7.  Clinical pharmacokinetics of carboplatin.

Authors:  W J van der Vijgh
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

Review 8.  Chemotherapy individualization.

Authors:  Gareth J Veal; Sally A Coulthard; Alan V Boddy
Journal:  Invest New Drugs       Date:  2003-05       Impact factor: 3.850

Review 9.  Practical treatment guide for dose individualisation in cancer chemotherapy.

Authors:  P Canal; E Chatelut; S Guichard
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

10.  A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve.

Authors:  S Ghazal-Aswad; A H Calvert; D R Newell
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.